Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 11, 2016 - Issue
Submit an article Journal homepage
88
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD

Xuehua Ke1 HealthCore Inc., Wilmington, DECorrespondence[email protected]
,
Jessica Marvel2 Novartis Pharmaceuticals Corporation, East Hanover, NJ
,
Tzy-Chyi Yu2 Novartis Pharmaceuticals Corporation, East Hanover, NJ
,
Debra Wertz1 HealthCore Inc., Wilmington, DE
,
Caroline Geremakis1 HealthCore Inc., Wilmington, DE
,
Liya Wang1 HealthCore Inc., Wilmington, DE
,
Judith J Stephenson1 HealthCore Inc., Wilmington, DE
&
David M Mannino3 University of Kentucky, Lexington, KY, USA
 show all
Pages 1689-1703 | Published online: 27 Jul 2016

Figures & data

Figure 1 Study design.

Figure 1 Study design.

Table 1 Baseline demographic and clinical characteristics from claims

Table 2 Baseline clinical characteristics from medical records

Figure 2 COPD exacerbations during the 12-month pre- and postindex periods.

Notes: Low FEV1% predicted defined as FEV1 <50% predicted; high FEV1% predicted defined as FEV1 $50% predicted. The hierarchy applied to create type of COPD exacerbation for an exacerbation episode was: inpatient COPD exacerbation > emergency department (ED) COPD exacerbation > ambulatory COPD exacerbation. A patient could have multiple types of COPD exacerbations within the baseline (12-month preindex period) and 12-month postindex periods.
Abbreviation: FEV1, forced expiratory volume in 1 second.
Figure 2 COPD exacerbations during the 12-month pre- and postindex periods.

Table 3 Baseline all-cause and COPD-related health care resource utilization and costs

Table 4 12-month postindex all-cause and COPD-related health care resource utilization and costs

Figure 3 Factors associated with COPD exacerbations within the 12-month postindex period.

Notes: Low FEV1% predicted defined as FEV1 <50% predicted; high FEV1% predicted defined as FEV1 $50% predicted. Logistic regression was performed with the dependent variable as the occurrence of COPD exacerbations within the 12-month postindex period. Odds ratios and 95% confidence intervals are reported in this figure.
Abbreviations: FEV1, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β2-adrenergic agonist; PDE4 inhibitors, phosphodiesterase-4 inhibitors.
Figure 3 Factors associated with COPD exacerbations within the 12-month postindex period.

Figure 4 Factors associated with COPD-related health care costs within the 12-month postindex period.

Notes: Low FEV1% predicted defined as FEV1 <50% predicted; high FEV1% predicted defined as FEV1 $50% predicted. Generalized linear models with gamma distribution and log link were performed with the dependent variable as COPD-related medical and pharmacy costs within the 12-month postindex period. Exponentiated coefficients and their corresponding 95% confidence intervals are reported in this figure.
Abbreviations: FEV1, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β2-adrenergic agonists; PDE4 inhibitors, phosphodiesterase-4 inhibitors.
Figure 4 Factors associated with COPD-related health care costs within the 12-month postindex period.

Figure S1 Claim-based sample identification process.

Note: *Index date, date of first medical claim for spirometry during intake period from July 1, 2012 to June 30, 2013.

Abbreviation: ED, emergency department.

Figure S1 Claim-based sample identification process.Note: *Index date, date of first medical claim for spirometry during intake period from July 1, 2012 to June 30, 2013.Abbreviation: ED, emergency department.

Figure S2 Medical record sample identification process.

Note: *Medical records received after medical record abstraction cutoff date.

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

Figure S2 Medical record sample identification process.Note: *Medical records received after medical record abstraction cutoff date.Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.